On a corporate action affecting ordinary shares of Cara Therapeutics, Inc. (CARA)

On December 18, 2024, Cara Therapeutics, Inc. entered into a merger agreement under which it will acquire Tvardi Therapeutics, Inc. The companies will combine a company under the name Tvardi Therapeutics, Inc. and ticker “TVRD”. Transaction is expected to close in the first half of 2025. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.